<DOC>
	<DOCNO>NCT00151320</DOCNO>
	<brief_summary>Primary Objective : To determine toxicity profile maximum tolerate dose ( MTD ) VELCADE administer combination CHOP + Rituximab patient previously untreated diffuse large B cell mantle cell non-Hodgkin 's lymphoma ( NHL ) Secondary Objectives : To assess response rate ( overall complete ) , event-free survival overall survival VELCADE CHOP-R patient previously untreated diffuse large B cell mantle cell lymphoma ( phase II component ) Treatment : Standard CHOP chemotherapy administer every 21 day ( full dose ) six cycle Rituximab administer ( 375 mg/m2 ) day 1 cycle ( usual premedications ) VELCADE administer prior rituximab CHOP day 1 cycle . The dose VELCADE determine follow dose escalation schedule : Level Dose/Schedule ( -2 ) 0.7 mg/m2 day 1 cycle ( -1 ) 0.7 mg/m2 day 1 8 ( 0 ) 0.7 mg/m2 day 1 4 ( +1 ) 1.0 mg/m2 day 1 4 ( +2 ) 1.3 mg/m2 day 1 4</brief_summary>
	<brief_title>Phase I/II Trial VELCADE + CHOP-Rituximab Untreated DLCBL Mantle Cell NHL</brief_title>
	<detailed_description>Standard CHOP chemotherapy administer every 21 day ( full dose ) six cycle Rituximab administer ( 375 mg/m2 ) day 1 cycle ( usual premedications ) VELCADE administer prior rituximab CHOP day 1 cycle . The dose VELCADE determine follow dose escalation schedule : Once complete six cycle therapy ( ~18 week ) , patient evaluate every 3 month first year post treatment , every 6 month disease progression death year 2 5 post treatment . Patients disease progression contact every 6 month death ass survival status .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm diagnosis diffuse large B cell mantle cell NonHodgkin 's Lymphoma characteristic immunophenotypic profile . For mantle cell : CD5 ( + ) , CD19 ( + ) CD20 ( + ) , cyclin D1 ( + ) , CD23 ( ) CD10 ( ) . Patient receive prior anticancer therapy lymphoma Tumor tissue confirm express CD20 antigen Available frozen tumor tissue ( rebiopsy need ) Patient measurable disease define tumor mass &gt; 1.5 cm Patient Stage II , III , IV disease Age &gt; 18 year Absolute granulocyte count &gt; 1000 cells/mm3 Platelet count &gt; 50,000 cells/mm3 Creatinine &lt; 2.0 x ULN Total bilirubin &lt; 2.0 x ULN Known central nervous system ( CNS ) involvement lymphoma Known HIV disease Patient pregnant nursing Patient major surgery within last 3 week Patient receive investigational drug Known peripheral neuropathy &gt; Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diffuse large B cell</keyword>
	<keyword>mantle cell lymphoma</keyword>
</DOC>